Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares, rose in value, with the stock price up by 1.82% to the previous day’s close as strong demand from buyers drove the stock to $8.93.
Actively observing the price movement in the last trading, the stock closed the session at $8.77. The value of beta (5-year monthly) was 0.83. Referring to stock’s 52-week performance, its high was $16.75, and the low was $4.54. On the whole, RXRX has fluctuated by -27.40% over the past month.
With the market capitalization of Recursion Pharmaceuticals Inc currently standing at about $1.93 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 06, 2024 – May 10, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.42, which is expected to increase to -$0.38 for fiscal year -$1.72 and then to about -$1.86 by fiscal year 2025. Data indicates that the EPS growth is expected to be -8.90% in 2025, while the next year’s EPS growth is forecast to be -8.10%.
Analysts have estimated the company’s revenue for the quarter at $12.65 million, with a low estimate of $10 million and a high estimate of $20.8 million. According to the average forecast, sales growth in current quarter could jump up 4.30%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $56.16 million, representing an increase of 26.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that RXRX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of RXRX currently trading nearly -16.14% and -19.32% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.22, while the 7-day volatility ratio is showing 4.97% which for the 30-day chart, stands at 7.84%. Furthermore, Recursion Pharmaceuticals Inc (RXRX)’s beta value is 0.77, and its average true range (ATR) is 0.87.
A comparison of Recursion Pharmaceuticals Inc (RXRX) with its peers suggests the former has fared considerably weaker in the market. RXRX showed an intraday change of 1.82% in last session, and over the past year, it grew by 33.88%%.
Data on historical trading for Recursion Pharmaceuticals Inc (NASDAQ:RXRX) indicates that the trading volumes over the past 10 days have averaged 5.5 million and over the past 3 months, they’ve averaged 7.21 million. According to company’s latest data on outstanding shares, there are 226.26 million shares outstanding.
Nearly 32.11% of Recursion Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 77.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 43.52 million shares as on Mar 15, 2024, resulting in a short ratio of 4.45. According to the data, the short interest in Recursion Pharmaceuticals Inc (RXRX) stood at 18.55% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 38.24 million. The stock has fallen by -9.43% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RXRX stock heading into the next quarter.
